BACKGROUND & AIMS:
C irrhosis is the end stage of any chronic liver Q10 disease and, based on a large body of evidence,
Q11
it now is classified into 2 distinct stages: compensated and decompensated. Each stage differs significantly in the prognosis, predominant pathophysiological mechanisms, and predictors of death. [1] [2] [3] [4] Nonselective b-blockers (NSBBs) have been the mainstay of therapy of portal hypertension since 1981 when Lebrec et al 5 showed the efficacy of propranolol in reducing portal pressure. Since then, many randomized controlled trials have shown that NSBBs are effective in preventing variceal hemorrhage, both first and recurrent, and therefore NSBBs are considered first-line therapy in the primary and secondary prophylaxis of variceal hemorrhage. 6 Because NSBBs, by reducing portal pressure, may prevent not only variceal hemorrhage but other complications of portal hypertension, many studies have correlated the decrease in portal pressure (as determined by the hepatic venous pressure gradient [HVPG] ) with the prevention of all complications of cirrhosis, including death. In a metaanalysis by D'Amico et al 7 that included 12 studies (including 943 patients with cirrhosis), HVPG responders, defined as those with an HVPG reduction to 12 mm Hg or less or 20% or more from baseline had a significantly lower risk of bleeding and death. However, all studies included in the D'Amico et al 7 meta-analysis combined results from patients with both compensated and decompensated cirrhosis.
Because the effect of NSBBs on portal pressure and outcomes may differ in these 2 different stages of cirrhosis 8 and because it has been suggested that NSBBs may be deleterious in patients with refractory ascites, 9, 10 we considered it important to update the D'Amico et al 7 meta-analysis by not only adding data from additional recent studies reporting HVPG response and outcomes but, more importantly, to stratify patients by the presence or absence of ascites and to report on clinically relevant outcomes. For this study, we considered ascites as the hallmark of decompensation because it is the most common decompensating event, it is the only one that is continuous (as opposed to variceal hemorrhage and hepatic encephalopathy, which are episodic), and because it is the most likely to be recorded accurately in study databases on which this meta-analysis was based.
Materials and Methods

Methods
We
Q12
performed a meta-analysis to pool data from patients with cirrhosis included in studies (randomized controlled trials or other) that assessed the difference in clinically relevant outcomes between HVPG responders and nonresponders relating to the 2 main prognostic stages of cirrhosis Q13 , compensated or decompensated, which in this study is defined as the absence or presence of ascites, respectively. This meta-analysis was conducted and reported according to the Quality Assessment of Systematic Reviews and Meta-Analyses of the National Institutes of Health, last updated in March 2014. 11 
Eligibility Criteria
Studies that included patients with cirrhosis and varices undergoing treatment with NSBBs to prevent first or recurrent esophageal variceal hemorrhage were included in this analysis if the following criteria were met: (1) patients included in the study had at least 2 measurements of HVPG performed, at baseline (before therapy) and during therapy; (2) the published report included the number of patients who were HVPG responders vs nonresponders; and (3) information regarding the presence or absence of ascites at baseline and relevant clinical outcomes during followup evaluation were available for each of the responder groups.
Exclusion Criteria
Case reports, editorials, letters, review articles, and guidelines were excluded from the analysis. We also excluded studies in which cirrhosis developed after liver transplantation. The D'Amico et al 7 meta-analysis found the long interval (5.3 mo) between HVPG measurements observed in 1 study 12 to be the main predictor of heterogeneity, therefore this study 12 and any other study with a mean/median interval between HVPG measurements of 5 months or longer were excluded.
Information Sources and Search
The studies conducted until December 2005 were identified from the D'Amico et al 7 meta-analysis. Studies conducted from January 1, 2006, to November 30, 2015, were identified by searching electronic databases using the terms "hepatic venous pressure gradient" or "HVPG," limiting the search to human studies. This search was performed in MEDLINE via PubMed, Embase using the ScienceDirect interface, and The Cochrane Central Register of Controlled Trials. Publications in personal reference lists and citation sections of the recovered 175  176  177  178  179  180  181  182  183  184  185  186  187  188  189  190  191  192  193  194  195  196  197  198  199  200  201  202  203  204  205  206  207  208  209  210  211  212  213  214  215  216  217  218  219  220  221  222  223  224  225  226  227  228  229  230  231  232 articles also were reviewed and abstracts presented at meetings of the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver were searched manually.
Study Selection and Data Collection Process
Two authors (L.T. and G.G.-T.) independently assessed titles and abstracts of studies identified in the primary search. If the title and/or abstract showed that the article did not meet inclusion criteria, the study was excluded. If the inclusion criteria could not be assessed from the title/abstract with certitude, the full-text article was evaluated to determine eligibility. Disagreements were resolved by discussion between L.T. and G.G.-T.
Once studies that met inclusion criteria had been selected and because data regarding the presence or absence of ascites and clinical outcomes specific for each of these subgroups and for each of the responder groups (responder vs nonresponder) could not be extracted from published studies, principal investigators of eligible studies were contacted to obtain data for all subgroups in their trials. Specifically, we provided a data collection form divided into HVPG responder vs nonresponder groups (providing the numbers for each group that had been reported in the published article), and the principal investigators then provided data on the presence or absence of ascites and on relevant clinical outcomes (see later) for each responder group separately. Therefore, this was not an individual meta-analysis and the objective was to analyze the development of clinical outcomes separately in HVPG responders vs nonresponders (as defined in each of the studies) stratified by the presence or absence of ascites. To include only unique patients, when the same patient population was used in multiple publications, the authors were asked to provide data from the most recent publication that included all patients (in which case the previous publication would not be considered) or to report only on the additional patients in the newer publication (in which case both publications would be cited). Authors were asked to exclude data from patients with only 1 HVPG measurement. The original data sets were checked for completeness and internal consistency and amended through correspondence with the principal investigators.
Data Collected on Outcomes
Relevant outcomes were defined separately for patients without ascites (compensated) and those with ascites (decompensated), as follows.
For patients without ascites, primary outcomes were the development of ascites, variceal hemorrhage (first in primary prophylaxis studies, recurrent in secondary prophylaxis studies), or encephalopathy. For patients with ascites, primary outcomes were the development of variceal bleeding (first in primary prophylaxis studies, recurrent in secondary prophylaxis studies) or refractory ascites, spontaneous bacterial peritonitis, hepatorenal syndrome, or encephalopathy. For patients in both groups, data were collected for both transplant and death. However, because the number of transplanted patients was small (n ¼ 76), death or transplant (death/ transplant) was used as a secondary end point.
Authors of each of the publications were asked to report on clinical outcome as follows: (1) bleeding or rebleeding alone (according to whether the patient was in a primary prophylaxis study/group or a secondary prophylaxis study/group; (2) bleeding or re-bleeding plus another outcome; and (3) any other clinical outcome without bleeding or re-bleeding. For the final analysis, all of these outcomes were combined. Careful initial evaluation was performed to ensure completeness of data, and to check the consistency of the results of the primary analyses for each trial with published reports.
Statistical Analysis
Meta-analyses were performed separately for patients without ascites and for those with ascites, and also was performed separately for patients enrolled in primary prophylaxis studies and those enrolled in secondary prophylaxis studies. Because the results of each study had dichotomous frequency data, a meta-analysis was performed by calculating odds ratios (ORs) and 95% CIs. Because the differences in the patients enrolled, the way the intervention was administered, and the way the outcome was measured may have had an impact on the magnitude of the effect, we chose to pool data and compare it using a random-effects model. 13 A P value less than .05 was considered significant. Statistical heterogeneity was calculated by the I 2 . Values less than 30%, 30% to 59%, 60% to 75%, and greater than 75% were classified as low, moderate, substantial, and considerable heterogeneity, respectively.
14 All analyses were performed using the software Review Manager (version 5.3; The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark).
Results
A total of 459 unique citations were identified using our search criteria (Supplementary Figure 1) . After excluding 420 studies because they did not report data on follow-up HVPG, 30 studies because they did not report on outcomes, and 1 study 15 because the median time between the baseline and follow-up HVPG was longer than 5 months (13 months in compensated patients and 8 months in decompensated patients), 8 studies published between January 2006 and November 2015 met our inclusion criteria. These 8 studies were added to 12 studies published before December 2005 as identified by D'Amico et al 7 ( Supplementary Figure 1) . We could not identify any eligible study published in abstract form that was not subsequently published in full.
Additional data on the outcomes of patients with and without ascites (separately) were requested from the authors of the 20 eligible studies. Original data were no longer available for 4 of them (including the study from McCormick et al 12 ) , and data from 1 publication 16 was duplicated in a second publication 17 and therefore was excluded. Therefore, the meta-analysis includes data from 15 studies [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] (Supplementary Figure 1) .
Characteristics of studies and patients. The characteristics of the 15 studies are shown in Table 1 . Ten studies were case-series and 5 were randomized controlled trials (RCT), and alcohol was the main etiology of cirrhosis in most studies.
Overall, the 15 selected studies included 1341 patients, of whom 228 were excluded (124 patients did not have a second HVPG performed, 72 patients had been reported in other studies, and 32 patients were tested after a single intravenous dose of propranolol). Therefore, data from 1113 unique patients were analyzed. Of these, 452 (40.6%) had ascites. Notably, and as expected, the mean HVPG levels were higher in patients with ascites than in those without ascites (Table 2) . Table 3 shows the different outcomes including death/liver transplant rates by the presence or absence of ascites, according to the HVPG response category (responders vs nonresponders), as defined in each of the studies. Except for 2 studies 19, 25 (all patients taking NSBBs for primary prophylaxis) defining HVPG responders as those patients achieving a reduction of more than 10% or a decrease to less than 12 mm Hg Q14 , the remaining 13 studies defined HVPG response as a decrease to less than 12 mm Hg or a reduction of more than 20% from baseline
Q15
. Notably, raw data were available for a study in which the original publication had defined only HVPG response as a decrease in HVPG to less than 12 mm Hg 20 so that response could be redefined as a decrease greater than 20% or a decrease less than 12 mm Hg to be consistent with the majority of studies. Table 3 also shows the specific pharmacologic therapy. Notably, of 1113 unique patients, only 145 (13%) were not on active pharmacologic treatment (39 were on placebo and 106 received endoscopic treatment only) ( Table 3 ). Supplementary Table 1 shows the HVPG methodology used in each study.
Patients Without Ascites (n¼ 661)
Q16
Of 661 patients without ascites, 332 did not have a history of variceal hemorrhage (included in primary prophylaxis studies) and 329 had a history of variceal hemorrhage (included in secondary prophylaxis studies).
Except for 85 patients (12.9%) analyzed in 2 studies 19, 25 in whom response was defined as an HVPG decrease of more than 10% or a decrease to less than 12 mm Hg (all patients taking NSBBs for primary prophylaxis), in the remaining 576 (87.1%) patients, HVPG response was defined as a decrease to less than 12 mm Hg or more than a 20% reduction from baseline.
Overall, responders (49.8%) had a significantly lower rate of clinical events (variceal hemorrhage, ascites, or encephalopathy) than nonresponders (OR, 0.35; 95% CI, 0.22-0.56) ( Figure 1A ), both in patients included in primary prophylaxis studies (OR, 0.28; 95% CI, 0.13-0.58) and in secondary prophylaxis studies (OR, 0.41; 95% CI, 0.22-0.78) without significant heterogeneity (P ¼ .10) ( Figure 1A ) Death/transplant rates also were significantly lower among responders (OR, 0.50; 95% CI, 0.32-0.78) ( Figure 1B 
Patients With Ascites (n ¼452)
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Of the 452 patients with ascites, 172 did not have a history of variceal hemorrhage (included in primary prophylaxis studies) and 280 had a history of variceal hemorrhage (included in secondary prophylaxis studies).
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Of note, the mean reduction in HVPG observed in patients with ascites (from 19.9 mm Hg at baseline to 17.2 mm Hg at follow-up evaluation, a decrease of 14%) was lower than that observed in patients without ascites (from 18.4 to 14.9 mm Hg, a decrease of 19%). In fact, the rate of HVPG responders was significantly lower in patients with ascites compared with those without ascites (42% vs 50%, respectively; P ¼ .0085). The highest HVPG response rate was observed in patients without ascites or variceal hemorrhage (VH) (50%), and the lowest HVPG response rate was in patients with ascites and prior VH (36%).
Patients Without Ascites Vs Patients With Ascites
Subgroup (no ascites vs ascites) difference testing in patients enrolled in primary and secondary prophylaxis studies was performed to assess whether the effects within each subgroup deviated significantly from the overall effect (Supplementary Figures 2-5) .
Primary prophylaxis studies. Subgroup difference testing showed no significant differences between patients with or without ascites when looking at HVPG response and the development of any clinical event (c 2 ¼ 0.31; df ¼ 1; P ¼ .58; I 2 ¼ 0%) (Supplementary Figure 2) or the death/transplant rate (c 2 ¼ 0.82; df ¼ 1; P ¼ .37; I 2 ¼ 0%) (Supplementary Figure 3) .
Secondary prophylaxis studies. Subgroup difference testing showed no significant differences between patients with or without ascites when looking at HVPG response and the development of any clinical event (c 2 ¼ 1.33; df ¼ 1; P ¼ .25; I 2 ¼ 25%) (Supplementary  Figure 4) or the death/transplant rate (c 2 ¼1.07, df ¼ 1; P ¼ .30; I 2 ¼ 6.8%) (Supplementary Figure 5) .
Discussion
This study shows that a reduction in portal pressure, as determined by predefined threshold reductions in HVPG, is associated with a lower rate of relevant outcomes both in patients with and without ascites. Because ascites is the hallmark of cirrhosis decompensation, our study shows that decreases in portal pressure are associated with better outcomes in both patients with compensated and decompensated cirrhosis and is proof that portal hypertension is a major mechanism in the development of both decompensation and further decompensation.
D'Amico et al 7 had already shown an association between a reduction in HVPG to levels less than 12 mm Hg or more than a 20% reduction from baseline and a reduced risk of variceal hemorrhage and death. Other studies also have shown that achievement of these hemodynamic targets leads to a reduced risk of developing ascites, spontaneous bacterial peritonitis, hepatorenal syndrome (HRS), and hepatic encephalopathy. 18 In patients with compensated cirrhosis who have never bled, it has been suggested that even a target HVPG reduction of more than 10% is associated with a reduced risk of developing ascites, variceal bleeding, refractory ascites, or HRS. 19 However, since the publication of these studies it has become clear that cirrhosis cannot be described as a single-stage disease and, with decompensation being the main determinant of prognosis, research on outcomes has to be analyzed separately by considering the 2 main prognostic stages of cirrhosis: compensated vs decompensated.
1-3 These 2 stages differ not only in terms of prognosis, but also in terms of the underlying pathophysiological drivers of disease progression 4, 32 and in terms of clinically relevant outcomes. The most important outcome in compensated patients is the development of decompensation and, in decompensated patients, the main outcome is mortality. 33 Therefore, in this meta-analysis we not only stratified patients by the absence or presence of ascites (as the surrogate for decompensation), but relevant clinical events were defined differently in each of the groups.
In the subgroup of patients without ascites (ie, compensated) we showed that decompensation (defined as development of ascites, VH, or encephalopathy) was reduced significantly in HVPG responders. This is not surprising in light of a recent double-blind RCT showing that NSBBs, compared with placebo, are associated with a lower rate of ascites development and are associated with a decrease in HVPG (PREDESCI Q18 RCT). 34 It is noteworthy to mention that all patients without ascites included in the studies analyzed in our meta-analysis had varices needing treatment and, therefore, by definition, had clinically significant portal hypertension similar to patients included in the PREDESCI RCT 34 but with more advanced portal hypertension. These are patients in whom hyperdynamic circulation already is present and the NSBB effect on HVPG is more pronounced. 4, 32 Importantly, HVPG response to NSBBs in our study was associated not only with a reduced risk of decompensation, but also with a reduced risk for death/liver transplantation in patients without ascites. 1161  1162  1163  1164  1165  1166  1167  1168  1169  1170  1171  1172  1173  1174  1175  1176  1177  1178  1179  1180  1181  1182  1183  1184  1185  1186  1187  1188  1189  1190  1191  1192  1193  1194  1195  1196  1197  1198  1199  1200  1201  1202  1203  1204  1205  1206  1207  1208  1209  1210  1211  1212  1213  1214  1215  1216  1217  1218   1219  1220  1221  1222  1223  1224  1225  1226  1227  1228  1229  1230  1231  1232  1233  1234  1235  1236  1237  1238  1239  1240  1241  1242  1243  1244  1245  1246  1247  1248  1249  1250  1251  1252  1253  1254  1255  1256  1257  1258  1259  1260  1261  1262  1263  1264  1265  1266  1267  1268  1269  1270  1271  1272  1273  1274 1275 1276 1277  1278  1279  1280  1281  1282  1283  1284  1285  1286  1287  1288  1289  1290  1291  1292  1293  1294  1295  1296  1297  1298  1299  1300  1301  1302  1303  1304  1305  1306  1307  1308  1309  1310  1311  1312  1313  1314  1315  1316  1317  1318  1319  1320  1321  1322  1323  1324  1325  1326  1327  1328  1329  1330  1331  1332  1333  1334   1335  1336  1337  1338  1339  1340  1341  1342  1343  1344  1345  1346  1347  1348  1349  1350  1351  1352  1353  1354  1355  1356  1357  1358  1359  1360  1361  1362  1363  1364  1365  1366  1367  1368  1369  1370  1371  1372  1373  1374  1375  1376  1377  1378  1379  1380  1381  1382  1383  1384  1385  1386  1387  1388  1389  1390  1391  1392 Results of this study in the subgroup of patients with ascites (ie, with decompensation) are particularly relevant in light of recent concerns about potential deleterious effects of NSBBs on renal function and a potential risk for increased mortality in patients with ascites. 9, 10 Even though, as previously shown, 4, 8 HVPG was higher at baseline in these patients and the rate of HVPG responders was lower than in patients without ascites, we could show that portal pressure reduction achieved by pharmacologic treatment was associated not only with a lower rate of further decompensation (defined as the development of VH, refractory ascites, spontaneous bacterial peritonitis, HRS), but also with a decrease in death/transplant in the overall group of patients with ascites. The decrease in death/transplant was significant in patients with a history of variceal hemorrhage (secondary prophylaxis studies), who likely represent a sicker patient population. Although we did not observe a significant benefit on the death/transplant rate in patients included in primary prophylaxis studies, there was no indication of a higher mortality rate in this group because the subgroup difference testing was not significant ( Figure 2B ). This lack of effect on survival already had been noted in previous meta-analyses 7, 35 and, in our study, this could have been because this was the smallest subgroup and rates of death/transplant were lower than expected based on other studies. In addition, although in patients with ascites who have bled from varices the main driver of mortality is the severity of portal hypertension (and therefore is affected by hemodynamic response), in patients without variceal hemorrhage confounders such as hepatocellular carcinoma, not directly related to hemodynamic changes, may contribute to overall mortality. We chose to analyze deaths/transplant jointly because of the multinational nature of the publications with different availability/ criteria for transplant and the timespan of the studies (with the earliest in 1990 when transplant rarely was performed). The number of transplants in the whole series was only 76, representing 23% of the combined death/transplant outcome. NSBB (propranolol, nadolol) were used in 87% of patients included in the meta-analysis and the remaining 13% were on a therapy without an effect on portal pressure (placebo or endoscopic therapy). A sensitivity analysis that excluded the 4 studies with patients on inactive therapy yielded the same results on outcomes and death/transplant rates (data shown in Supplementary Table 2) .
Our meta-analysis is unique in that not only did we explore outcomes other than variceal hemorrhage and death, but we explored outcomes relevant to each prognostic stage. In addition, because data were requested from the original authors, we could ensure that duplicate patients were excluded and, therefore, unlike other metaanalyses that extracted data from publications that had duplicate patients, we report data on unique patients with cirrhosis.
Limitations of the study were those inherent to the collection of retrospective selected data from prospective studies. In addition, some important variables such as comorbidities, hepatocellular carcinoma, Child-Pugh score, and model for end-stage liver disease, were not collected uniformly, therefore we were not able to explore the impact of these predictive scores on outcomes. Notably, although the second most common etiology was viral, all studies were performed before the advent of effective antiviral therapy and such therapy therefore would not represent a confounder. A potential confounder was the use (or not) of alcohol during the study. Although alcohol was the etiology in fewer than half of the patients (n ¼ 516), 9 of 15 studies reported on alcohol abstinence during the follow-up evaluation. Of these, 2 studies 20, 22 reported that all patients had been abstinent during the study, 5 studies 18, 19, 25, 27, 31 showed no significant differences between alcohol abstinence/ nonabstinence and HVPG response/nonresponse, and only 2 studies 17,29 comprising only 110 patients found a higher percentage of alcohol abstinence among HVPG responders compared with nonresponders. Therefore, it is unlikely that better outcomes in HVPG responders observed in this meta-analysis could have been ascribed to alcohol abstinence.
Reductions in HVPG all were described as threshold reductions (responders vs nonresponders) in the studies included in this meta-analysis. It may well be that analysis of absolute changes in mm Hg could provide more granularity (as recently described 36 ), but data on individual data
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were not requested from the original authors (only data on responders vs nonresponders), and therefore such analysis could not be performed.
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